NCT03290898

Brief Summary

To evaluate if physical exercise intervention leads to an improved asthma control as measured by Asthma Control Questionnaire (ACQ-5) in such a magnitude that inhaled corticosteroid can be reduces in asthmatics.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for not_applicable asthma

Timeline
Completed

Started Oct 2017

Typical duration for not_applicable asthma

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 18, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 25, 2017

Completed
18 days until next milestone

Study Start

First participant enrolled

October 13, 2017

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 26, 2020

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 4, 2020

Completed
Last Updated

March 15, 2021

Status Verified

March 1, 2021

Enrollment Period

2.7 years

First QC Date

September 18, 2017

Last Update Submit

March 11, 2021

Conditions

Keywords

AsthmaExerciseAsthma treatmentInhaled corticosteroidRehabilitation

Outcome Measures

Primary Outcomes (1)

  • Reduced inhaled corticosteroid (ICS) 6 months

    The proportion of participants at 6 months that have been down-titrated in ICS dose by at least 25% compared to the participants' baseline dose

    6 months +/- 7 days

Secondary Outcomes (22)

  • Reduced inhaled corticosteroid (ICS) 12 months

    12 months +/- 7 days

  • Cumulated ICS 6 months

    6 months +/- 7 days

  • Cumulated ICS 12 months

    12 months +/- 7 days

  • Cumulated Long acting beta2 agonists (LABA) 6 months

    6 months +/- 7 days

  • Cumulated LABA 12 months

    12 months +/- 7 days

  • +17 more secondary outcomes

Other Outcomes (2)

  • Eosinophilic subpopulation - exploratory analyses 6 months

    6 months +/- 7 days

  • Eosinophilic subpopulation - exploratory analyses 12 months

    12 months +/- 7 days

Study Arms (2)

Training group

ACTIVE COMPARATOR

Supervised High intensity interval training (HIIT) 3 times a week for 6 months. Training session: 10 minutes warm up (Low-moderate intensity) 30 minutes intervention (16 minutes HIIT) 10 minutes cool down(Low-moderate intensity)

Behavioral: High Intensity Interval Training

Control group

NO INTERVENTION

Control group, usual lifestyle. Aside from training intervention, all other visits are the same as intervention group (training).

Interventions

Training (HIIT)

Also known as: Training group
Training group

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Asthma (The diagnose of asthma is based on symptoms and at least one positive asthma test the last 5 years (AHR to either mannitol or methacholine, reversibility to beta2-agonist, peak flow variation or positive eucapnic voluntary hyperventilation test))
  • ACQ ≥ 1 and ≤ 2.5
  • On a daily dose of ICS at a minimum of 400 µg budesonide or equivalent ICS for 3 months and with no changes in asthma medicine 4 weeks prior to enrollment
  • Untrained (no participation in vigorous exercise for more than 1 hour per week during the last 2 month)
  • Capable of exercising on bike

You may not qualify if:

  • Unable to speak and understand Danish
  • Infection within 4 weeks prior to visit 100\*
  • Asthma exacerbation within 4 weeks prior to visit 100\*
  • Hospitalized for an asthma attack during the last 2 months
  • Treatment with immunotherapy within 5 T½ of the treatment drug prior to visit 100
  • Initiation of allergen immunotherapy within 3 months prior to visit 100 or plan to begin therapy during study period
  • Treatment with peroral prednisolone
  • Respiratory: other chronic pulmonary disease of clinically significance
  • Cardiovascular: Unstable ischemic heart disease, myocardial infarction within the last 12 months, symptomatic heart failure (NYHA III-IV or EF \<40%), symptomatic heart arrhythmia (documented with ECG), uncontrolled hypertension (\>155/100)
  • Pregnancy or breastfeeding or planned pregnancy within the next 12 months
  • Other inflammatory or metabolic diseases with the exception of rhinitis, atopy and well-controlled hypothyroidism treated with or without Eltroxin
  • Vaccination less than 2 weeks prior to any visit
  • Current or former smokers with \> 20 pack years
  • Subjects, who by investigators determination, will not be able to adhere to study protocol
  • If patients are excluded due to a recent infection or exacerbation they can undergo re-screening after a total of 4 weeks after end of exacerbation treatment/clearing the infection.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Respiratory Research Unit, Birpebjerg Hospital

Copenhagen NV, 2400, Denmark

Location

Related Publications (1)

  • Pitzner-Fabricius A, Dall CH, Henriksen M, Hansen ESH, Toennesen LL, Hostrup M, Backer V. Effect of High-Intensity Interval Training on Inhaled Corticosteroid Dose in Asthma Patients: A Randomized Controlled Trial. J Allergy Clin Immunol Pract. 2023 Jul;11(7):2133-2143.e8. doi: 10.1016/j.jaip.2023.04.013. Epub 2023 May 31.

MeSH Terms

Conditions

AsthmaMotor Activity

Interventions

High-Intensity Interval TrainingSensitivity Training Groups

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesBehavior

Intervention Hierarchy (Ancestors)

Physical Conditioning, HumanExerciseMotor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaPsychotherapy, GroupSocioenvironmental TherapyPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Vibeke Backer, professor

    Rigshospitalet, Denmark

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Single blindet, randomization and training intervention by non-investigator. Open-label after primary follow up. After unblinding, blindet 3rd party performs tests (visit 9 and 12 months, e.g. spirometry)
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: A randomized, controlled parallel group, outcome assessor blinded, clinical trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor dr.med.

Study Record Dates

First Submitted

September 18, 2017

First Posted

September 25, 2017

Study Start

October 13, 2017

Primary Completion

June 26, 2020

Study Completion

December 4, 2020

Last Updated

March 15, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share

Locations